You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 2
  • 1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)

Article metrics

Article menu

Download PDFPDF

Late-Breaking Abstracts
Clinical Trial Completed
1518 T-cell inducing oncolytic virus (igrelimogene litadenorepvec; TILT-123) shows safety, anti-tumor activity and induction of immune responses in advanced solid tumor patients (full report on TUNIMO)

 

Online download statistics by month:

Online download statistics by month: October 2023 to June 2025

AbstractFullPdf
Oct 2023602
Nov 2023202015
Dec 20234305
Jan 20244401
Feb 20244205
Mar 20246005
Apr 20246205
May 20246604
Jun 20246608
Jul 20245004
Aug 20243605
Sep 20246804
Oct 202458013
Nov 20248406
Dec 20248208
Jan 20259604
Feb 20254607
Mar 2025002
Apr 2025103
May 2025005
Jun 2025205
Total11140116